SPDR Gold Trust vs Liquidia Corporation Common Stock — how do they compare? SPDR Gold Trust trades at $380.5 (market cap $141.50B), while Liquidia Corporation Common Stock trades at $33.47 (market cap $3.04B). The key difference: SPDR Gold Trust is far larger — about 46.5× Liquidia Corporation Common Stock's market cap, and Liquidia Corporation Common Stock is more actively traded (21,111,778 versus 5,707,251). Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 75 Days and Liquidia Corporation Common Stock for 0 Days on average.
| GLD | LQDA | |
|---|---|---|
Market Cap | $141.50B | $3.04B |
Volume | 5,707,251 | 21,111,778 |
52-Week High | $495.90 | $91.03 |
52-Week Low | $362.32 | $22.02 |
Typical Hold Time | 75 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $2.94B |
Signals from Pluang's Aura AI — not financial advice
GLD, the SPDR Gold Trust ETF, trades at $381.67, down 0.13% amid pressure from rising Treasury yields and a stronger U.S. dollar. Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators remain neutral. Recent news highlights gold's struggle to maintain momentum despite safe-haven demand, with prices testing key support levels near $380.
The outlook for GLD hinges on interest rate trends and macroeconomic uncertainty. While gold serves as a hedge against inflation and debt concerns, near-term headwinds from elevated yields and Fed policy uncertainty pose risks. A tactical buying opportunity may emerge if support holds, but sustained gains require a shift in monetary policy sentiment.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →